QIAGEN N.V. Announces Key Terms for Convertible Bonds
VENLO, The Netherlands – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced crucial details about its new senior, unsecured, net share settled convertible bonds. This offering is expected to raise a total principal amount of $500 million, which will enhance the company's financial flexibility.
Details of the Convertible Bonds Offering
The newly structured convertible bonds will mature in 2031, with an initial conversion price set at $64.0129 per share. This represents a significant premium of 44% over the current reference share price of $44.4534 per share. When bondholders choose to exercise their conversion rights, they will receive cash equivalent to the bonds' par value along with shares that together equal the total value of the shares associated with the bonds.
Expected Settlement and Use of Proceeds
The anticipated settlement date for these bonds is September 10, 2024. QIAGEN intends to apply for these bonds to be traded on the Open Market segment of the Frankfurt Stock Exchange. The funds raised from this offering will mainly be used to support general corporate needs, including refinancing existing debts.
Commitment to Investors
As part of the offering process, QIAGEN has committed to a lock-up period, during which it will refrain from selling any comparable securities for 90 days following the settlement. This restriction will include certain exceptions that depend on agreements with the joint global coordinators.
About QIAGEN N.V.
QIAGEN N.V. is a leader in innovation within the life sciences sector, offering comprehensive Sample to Insight solutions. These solutions empower researchers and healthcare professionals to derive meaningful molecular insights from biological samples such as blood and tissue. QIAGEN’s cutting-edge technologies and bioinformatics capabilities support over 500,000 clients worldwide, covering the fields of Molecular Diagnostics and Life Sciences.
Workforce and Global Reach
With a dedicated team of over 5,900 employees, QIAGEN operates in more than 35 locations across the globe, demonstrating its commitment to delivering high-quality solutions that advance molecular research and diagnostics.
Contact Information
If you have questions regarding investor relations, you can reach out to John Gilardi and Domenica Martorana at +49 2103 29 11711 and +49 2103 29 11244, respectively. For public relations inquiries, Dr. Thomas Theuringer and Lisa Specht are available at +49 2103 29 11826 and +49 2103 29 14181. You can also email investor inquiries at ir@QIAGEN.com and public relations inquiries at pr@QIAGEN.com.
Frequently Asked Questions
What are convertible bonds?
Convertible bonds are debt securities that give investors the option to convert them into a specific number of shares, typically at a designated time and price.
What will QIAGEN do with the proceeds from the bonds?
QIAGEN plans to utilize the proceeds for general corporate purposes, primarily focusing on refinancing existing debts.
What is the significance of the conversion price?
The conversion price is important because it sets the rate at which bondholders can convert their bonds into shares, influencing both equity valuation and the appeal to investors.
When is the expected settlement date of the bonds?
The expected settlement date for the new convertible bonds is September 10, 2024.
How does QIAGEN rank in the biopharmaceutical industry?
QIAGEN is recognized as a prominent provider of molecular testing and sample technologies, catering to various sectors including healthcare and research.
